Bromocriptine and uterine neoplasia.

Griffith, R.W.

doi:10.1136/bmj.2.6102.1605-a

Cited by 24 publications

(14 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In rats and rabbits,no deaths occur at the highest acute doses that can be administered orally (in excess of 1 and 2 g/kg, respectively), while the LDSo (lethal dose for half the animals) for acute intravenous administration is 12.5,72, and 190 nig/kg for rabbits, rats, and mice, respectively (Grauwiler & Griffith, 1974). In prolonged studies, where high doses of bromocriptine have been administered daily for many weeks, specific toxic effects have not emerged in rats (Griffith, 1974(Griffith, , 1977, dogs (Griffith & fichardson, 1975) or rhesus monkeys (Griffith, 1976), although transient excitability and some weight changes (probably secondarily associated with the endocrine changes) have been encountered at high dose levels. Surprisingly, prolonged treatment with bromocriptine actually has some beneficial effects including a reduction in the incidence of certain tumors (Fluckiger, 1980;Griffith, 1977).…”

Section: Toxicitymentioning

confidence: 99%

The lactation–blocking drug bromocriptine and its application to studies of weaning and behavioral development

Martin

Bateson

1982

Developmental Psychobiology

View full text Add to dashboard Cite

An experimental method for blocking maternal lactation is reviewed and the possible application of this technique for experimentally manipulating weaning is considered. Maternal milk production can be inhibited using the prolactin-suppressing drug bromocriptine. The suitability of bromocriptine for use in behavioural experiments is considered. The pharmacology of bromocriptine (CB 154) is briefly outlined and a compilation of the reported lactation-inhibiting doses for various species is presented. The possible endocrine and behavioral side-effects and the toxicity of the drug are discussed. It is concluded that, in most species studied so far, the drug is relatively free from significant side-effects at the low doses needed to suppress lactation. Guidelines for the practical use of bromocriptine are suggested. Finally, some ideas about the possible application of the drug to the study of behavioral development and parent-offspring relationships are discussed.

show abstract

Section: Toxicitymentioning

confidence: 99%

The lactation–blocking drug bromocriptine and its application to studies of weaning and behavioral development

Martin

Bateson

1982

Developmental Psychobiology

View full text Add to dashboard Cite

show abstract

“…anti-dsDNA and anticardiolipin autoantibodies [ 18]. In female rats, a reduction in the incidence and severity of PN and a decreased incidence of spontaneous mammary tumours were obtained with CB-154 [14]. In our study, long-term treatment of male Sprague-Dawley rats with CBLA alone reduced the incidence and severity of PN in a dose-dependent manner; CsA alone was less potent than CBLA alone, and only additive effects were obtained.…”

Section: Discussionmentioning

confidence: 39%

“…PN in rats is an age-related autoimmune process, in which endocrine dysregulations might play a role. Thus, PN is induced by chronic administration of oestrogen [13], while in female rats, the disease is prevented by long-term treatment with CB-154 [14]. Finally, the BB rat is accepted as the most useful animal model of human type I (insulin-dependent) diabetes.…”

mentioning

confidence: 99%

Synergism between long-acting bromocryptine microcapsules and cyclosporine A in the prevention of various autoimmune diseases in rats

Neidhart

1996

Experientia

View full text Add to dashboard Cite

Pre-treatment of male Sprague-Dawley rats with long-acting bromocryptine microcapsules (CBLA) significantly inhibited the arthritic response to Freund's complete adjuvant and reduced weight loss, thymolysis, splenomegaly and leukocytosis. In the prevention of adjuvant arthritis (AA), the combination of CBLA plus sub-optimal doses of cyclosporine A (CsA) was more efficient than either of the drugs alone. Sub-optimal doses of CsA were 0.1 and 1.0 mg/kg/day s.c. for 5 days. Furthermore, CBLA alone did not decrease the incidence of experimental allergic uveitis (EAU) in the male Lewis rats. Low-dose CsA reduced the incidence of uveitis by 50%, and with the addition of CBLA, 100% of rats were protected. Low-dose CsA was 2 mg/kg/day i.m. for 14 days. Long-term treatment of male Sprague-Dawley rats with CBLA alone reduced the incidence and severity of spontaneous autoimmune periarteritis nodosa (PN) in a dose-dependent manner; CsA was less potent than CBLA, and only additive effects were obtained. Finally, for the prevention of spontaneous autoimmune insulin-dependent diabetes (DM), the administration of CBLA did not improve the effect of a low-dose CsA in male BB rats. Nevertheless, a delay in onset of DM could be achieved. A sequential therapy using CsA plus CBLA clearly showed beneficial effects. The dose of CsA was 10 mg/kg p.o. 6 days/week for 21 weeks. Compared with Sprague-Dawley or Lewis male rats, BB male rats showed only weak prolactin suppression after the same doses of CBLA. It is suggested that the use of CBLA may be particularly beneficial in autoimmune disorders. The effectiveness of the combination therapy CBLA plus CsA, however, was dependent on the model considered. Various factors could play a role: (1) the different ways of administering CsA (s.c. in AA, i.m. in EAU and PN, oral in DM); (2) strain-dependency in the capacity of CBLA to suppress Prl secretion; and (3) at least in the BB rats, the transient increase of CsA bioavailibility which was possibly induced by CBLA.

show abstract

“…In addition, treated male animals have a decreased mortality rate, decreased incidence of benign adrenal tumors and a decreased incidence of chronic progressive nephropathy, when compared with untreated animals. Both sexes develop a treatment‐related decrease in food intake/body weight gain (Griffith, ; Richardson et al , ). Further studies have also demonstrated that the dosing of bromocriptine can inhibit DNA synthesis, mitosis and hormone secretion in spontaneously occurring rodent pituitary tumors (Prysor‐Jones and Jenkins, ).…”

Section: Preclinical Detection Of Drug‐induced Hypo‐/hyperprolactinemiamentioning

confidence: 99%

“…Regarding the possible association of prolonged hypoprolactemia with tumorigenesis, the initial finding of uterine tumors in rats treated with bromocriptine for a period of 100 weeks sparked a flurry of clinical investigation to ascertain the human relevance of this finding (Besser et al , ; Griffith, ; Anonymous, ). Besser et al () conducted a study analyzing 108 women who had been treated with bromocriptine for up to six years.…”

Section: Clinical Relevance Of Drug‐induced Hypo‐/hyperprolactinemiamentioning

confidence: 99%

Preclinical risk assessment of drug‐induced hypo‐ and hyperprolactinemia

Hargreaves

Harleman

2011

J of Applied Toxicology

View full text Add to dashboard Cite

Drug-induced changes in prolactin signaling may obscure interpretation of preclinical toxicological endpoints. However, with informed consideration, classic hallmarks of hypo-/hyperprolactinemia can be recognized in short- and long-term rodent bioassays. Findings can be supported and expanded with additional in vivo and in vitro datasets. When taken together with human epidemiological evidence pertaining to the consequences of drug-induced hypo-/hyperprolactinemia, such findings permit both an analysis of human relevance and an assessment of human risk.

show abstract

Bromocriptine and uterine neoplasia.

Cited by 24 publications

References 0 publications

The lactation–blocking drug bromocriptine and its application to studies of weaning and behavioral development

The lactation–blocking drug bromocriptine and its application to studies of weaning and behavioral development

Synergism between long-acting bromocryptine microcapsules and cyclosporine A in the prevention of various autoimmune diseases in rats

Preclinical risk assessment of drug‐induced hypo‐ and hyperprolactinemia

Contact Info

Product

Resources

About